{
  "docId": "019de071-94a0-75ef-b86b-e4894fa7dc1d",
  "docSlug": "8b4d61768a47893d5f24ee0f1f9ae717",
  "documentTitle": "argenx SE | Results Presentation Deck | 20 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 20,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "comparison_table",
  "function": "present_solution",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a comparison matrix structure to justify expanding the company's 'skin franchise' into a new indication.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-94a0-75ef-b86b-e4894fa7dc1d/10",
  "deckHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d",
  "deckJsonHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d.json",
  "deckAnchorHref": "/decks/019de071-94a0-75ef-b86b-e4894fa7dc1d#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "callout",
      "text": "Registrational trial to start by end of year in parallel to ongoing pemphigus trial",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dfe30b7-9fab-4407-9d34-68d4c4078e7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.86,
        "x": 0.07,
        "y": 0.2
      },
      "kind": "table",
      "text": "Comparison matrix of Pemphigus vs Pemphigoid across Autoantibody Driven, Convincing Rationale, Unmet Patient Needs, and Primary Endpoint.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d60916f5-3b12-4f23-8736-d7fb8b07fa3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Bullous Pemphigoid: Expanding the Skin Franchise",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a0fdb21-9041-41f9-a2a2-761dcea1a79a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "ede60796-9656-404a-8a88-5109f6ef81f2",
      "evidence": "Comparison matrix of Pemphigus vs Pemphigoid across Autoantibody Driven, Convincing Rationale, Unmet Patient Needs, and Primary Endpoint.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "6097ff96-c9c7-43ec-95be-ad7aab2e3192",
      "evidence": "The slide compares two disease states across four specific clinical dimensions.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 7,
      "beatId": "3c157cf2-a15a-4adb-bf74-d8b7db4a16f5",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "What Is",
      "beatSlug": "sparkline-what-is-3",
      "evidence": "The roadmap slides present the current pipeline and development plans",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}